{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:20:23Z","timestamp":1790958023538,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Signs and symptoms of Bardet\u2013Biedl syndrome (BBS) occur during early childhood, progress over time, and place substantial, multifaceted burden on patients and their caregivers. Hyperphagia may be a contributing factor to early-onset obesity in BBS; however, there are limited insights into its impacts on patients and caregivers. We quantified disease burden as it relates to the physical and emotional impacts of hyperphagia in BBS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The CAREgiver Burden in BBS (CARE-BBS) study was a multicountry, cross-sectional survey of adult caregivers of patients with BBS who have had hyperphagia and obesity. The survey consisted of questionnaires including Symptoms of Hyperphagia, Impacts of Hyperphagia, Impact of Weight on Quality of Life (IWQOL)-Kids Parent Proxy, and Patient-Reported Outcome Measurement Information System (PROMIS) v1.0-Global Health 7. In addition, clinical characteristics, medical history, and weight management questions were included. Outcomes were scored and summarized descriptively in aggregate and by country, age, and obesity severity according to weight class.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 242 caregivers of patients with BBS who completed the survey. Caregivers observed hyperphagic behaviors throughout the day, with negotiating for food (90%) and waking up and asking or looking for food during the night (88%) being the most frequent. Hyperphagia had at least a moderate negative impact on most patients\u2019 mood\/emotions (56%), sleep (54%), school (57%), leisure (62%), and familial relationships (51%). Hyperphagia affected concentration at school (78%), and symptoms of BBS contributed to patients missing\u2009\u2265\u20091\u00a0day of school a week (82%). Responses from the IWQOL-Kids Parent Proxy suggested obesity most greatly negatively affected physical comfort (mean [standard deviation (SD)], 41.7 [17.2]), body esteem (41.0 [17.8]), and social life (41.7 [18.0]). On the PROMIS questionnaire, mean (SD) global health score for pediatric patients with BBS and overweight or obesity (36.8 [10.6]) was lower than the general population (mean, 50).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evidence from this study suggests that hyperphagia and obesity may have broad negative impacts on the lives of patients with BBS, including physical health, emotional well-being, school performance, and personal relationships. Therapies that target hyperphagia may alleviate the extensive clinical and nonclinical impacts experienced by patients with BBS and their caregivers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02723-4","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T23:03:20Z","timestamp":1688684600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Burden of hyperphagia and obesity in Bardet\u2013Biedl syndrome: a multicountry survey"],"prefix":"10.1186","volume":"18","author":[{"given":"Elizabeth","family":"Forsythe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha G.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Cala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Greatsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Hagopian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-4982","authenticated-orcid":false,"given":"Andrea M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"2","key":"2723_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/PGE-13051","volume":"2","author":"S Castro-S\u00e1nchez","year":"2013","unstructured":"Castro-S\u00e1nchez S, \u00c1lvarez-Satta M, Cort\u00f3n M, Guill\u00e9n E, Ayuso C, Valverde D. Bardet\u2013Biedl syndrome: a rare genetic disease. J Pediatr Genet. 2013;2(2):77\u201383.","journal-title":"J Pediatr Genet"},{"key":"2723_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fped.2018.00023","volume":"6","author":"E Forsythe","year":"2018","unstructured":"Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet\u2013Biedl syndrome-now and in the future. Front Pediatr. 2018;6:23.","journal-title":"Front Pediatr"},{"issue":"1","key":"2723_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ejhg.2012.115","volume":"21","author":"E Forsythe","year":"2013","unstructured":"Forsythe E, Beales PL. Bardet\u2013Biedl syndrome. Eur J Hum Genet. 2013;21(1):8\u201313.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"2723_CR4","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/j.2047-6310.2013.00182.x","volume":"8","author":"R Sherafat-Kazemzadeh","year":"2013","unstructured":"Sherafat-Kazemzadeh R, Ivey L, Kahn SR, Sapp JC, Hicks MD, Kim RC, et al. Hyperphagia among patients with Bardet\u2013Biedl syndrome. Pediatr Obes. 2013;8(5):e64\u20137.","journal-title":"Pediatr Obes"},{"key":"2723_CR5","unstructured":"Forsythe et al. Quality of life in patients with Bardet\u2013Biedl syndrome in a setmelanotide phase 3 trial. Poster presented at: ObesityWeek 2021; November 1\u20135, 2021; virtual."},{"issue":"2","key":"2723_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12703","volume":"16","author":"J Pomeroy","year":"2021","unstructured":"Pomeroy J, Krentz AD, Richardson JG, Berg RL, VanWormer JJ, Haws RM. Bardet\u2013Biedl syndrome: weight patterns and genetics in a rare obesity syndrome. Pediatr Obes. 2021;16(2): e12703.","journal-title":"Pediatr Obes"},{"issue":"2","key":"2723_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005890","volume":"12","author":"DF Guo","year":"2016","unstructured":"Guo DF, Cui H, Zhang Q, Morgan DA, Thedens DR, Nishimura D, et al. The BBSome controls energy homeostasis by mediating the transport of the leptin receptor to the plasma membrane. PLoS Genet. 2016;12(2): e1005890.","journal-title":"PLoS Genet"},{"issue":"1","key":"2723_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cge.13367","volume":"95","author":"E Geets","year":"2019","unstructured":"Geets E, Meuwissen MEC, Van Hul W. Clinical, molecular genetics and therapeutic aspects of syndromic obesity. Clin Genet. 2019;95(1):23\u201340.","journal-title":"Clin Genet"},{"issue":"2","key":"2723_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ajhg.2015.04.023","volume":"99","author":"A Lindstrand","year":"2016","unstructured":"Lindstrand A, Frangakis S, Carvalho CM, Richardson EB, McFadden KA, Willer JR, et al. Copy-number variation contributes to the mutational load of Bardet\u2013Biedl Syndrome. Am J Hum Genet. 2016;99(2):318\u201336.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"2723_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41436-020-0761-1","volume":"22","author":"HE Shamseldin","year":"2020","unstructured":"Shamseldin HE, Shaheen R, Ewida N, Bubshait DK, Alkuraya H, Almardawi E, et al. The morbid genome of ciliopathies: an update. Genet Med. 2020;22(6):1051\u201360.","journal-title":"Genet Med"},{"issue":"7","key":"2723_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/hmg\/ddp031","volume":"18","author":"S Seo","year":"2009","unstructured":"Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet\u2013Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18(7):1323\u201331.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2723_CR12","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1172\/JCI62696","volume":"122","author":"ME Doche","year":"2012","unstructured":"Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh JM, Henning E, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest. 2012;122(12):4732\u20136.","journal-title":"J Clin Invest"},{"issue":"3","key":"2723_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000445061","volume":"9","author":"H Huvenne","year":"2016","unstructured":"Huvenne H, Dubern B, Clement K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158\u201373.","journal-title":"Obes Facts"},{"issue":"4","key":"2723_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2020.103856","volume":"63","author":"D Zelihi\u0107","year":"2020","unstructured":"Zelihi\u0107 D, Hjardemaal FR, Lippe CV. Caring for a child with Bardet\u2013Biedl syndrome: a qualitative study of the parental experiences of daily coping and support. Eur J Med Genet. 2020;63(4): 103856.","journal-title":"Eur J Med Genet"},{"issue":"10","key":"2723_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140705","volume":"10","author":"B Hamlington","year":"2015","unstructured":"Hamlington B, Ivey LE, Brenna E, Biesecker LG, Biesecker BB, Sapp JC. Characterization of courtesy stigma perceived by parents of overweight children with Bardet\u2013Biedl Syndrome. PLoS ONE. 2015;10(10): e0140705.","journal-title":"PLoS ONE"},{"key":"2723_CR16","unstructured":"Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Haqq AM, et al. Patient- and caregiver-reported experiences of hyperphagia in Bardet\u2013Biedl syndrome before and during setmelanotide treatment. Poster presented at: The Pediatric Endocrine Society Annual Meeting 2022; April 28-May 1, 2022; virtual."},{"issue":"10","key":"2723_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046924","volume":"7","author":"C Sikorski","year":"2012","unstructured":"Sikorski C, Luppa M, Br\u00e4hler E, K\u00f6nig HH, Riedel-Heller SG. Obese children, adults and senior citizens in the eyes of the general public: results of a representative study on stigma and causation of obesity. PLoS ONE. 2012;7(10): e46924.","journal-title":"PLoS ONE"},{"issue":"1","key":"2723_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jadohealth.2010.10.005","volume":"49","author":"K Nadeau","year":"2011","unstructured":"Nadeau K, Kolotkin RL, Boex R, Witten T, McFann KK, Zeitler P, et al. Health-related quality of life in adolescents with comorbidities related to obesity. J Adolesc Health. 2011;49(1):90\u20132.","journal-title":"J Adolesc Health"},{"issue":"4","key":"2723_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s11136-013-0581-8","volume":"23","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Bevans KB, Pratiwadi R, Moon J, Teneralli RE, Minton JM, et al. Development of the PROMIS \u00ae pediatric global health (PGH-7) measure. Qual Life Res. 2014;23(4):1221\u201331.","journal-title":"Qual Life Res"},{"key":"2723_CR20","unstructured":"CDC: Modified Z-score in the CDC growth charts. https:\/\/www.cdc.gov\/nccdphp\/dnpa\/growthcharts\/resources\/biv-cutoffs.pdf (2022). Accessed 9 Sept 2022."},{"key":"2723_CR21","doi-asserted-by":"crossref","unstructured":"Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999\u20132016. Pediatrics. 2018;141(3).","DOI":"10.1542\/peds.2017-3459"},{"key":"2723_CR22","unstructured":"CDC: Defining adult overweight & obesity. https:\/\/www.cdc.gov\/obesity\/basics\/adult-defining.html (2022). Accessed 29 Aug 2022."},{"issue":"3","key":"2723_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709\u201357.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2723_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/oby.2006.59","volume":"14","author":"RL Kolotkin","year":"2006","unstructured":"Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA, et al. Assessing weight-related quality of life in adolescents. Obesity (Silver Spring). 2006;14(3):448\u201357.","journal-title":"Obesity (Silver Spring)"},{"key":"2723_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-11-29","volume":"11","author":"DT Selewski","year":"2013","unstructured":"Selewski DT, Collier DN, MacHardy J, Gross HE, Pickens EM, Cooper AW, et al. Promising insights into the health related quality of life for children with severe obesity. Health Qual Life Outcomes. 2013;11:29.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2723_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.7570\/jomes.2019.28.4.246","volume":"28","author":"JW Blanchett","year":"2019","unstructured":"Blanchett JW, Kuhlmann NA, Fidai MS, Borowsky PA, Muh SJ, Makhni EC. Using patient-reported outcome measurement information system computer adaptive testing domains to investigate the impact of obesity on physical function, pain interference, and mental health in sports medicine patients. J Obes Metab Syndr. 2019;28(4):246\u201353.","journal-title":"J Obes Metab Syndr"},{"issue":"4","key":"2723_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/chi.2021.0003","volume":"17","author":"AM Haqq","year":"2021","unstructured":"Haqq AM, Kebbe M, Tan Q, Manco M, Salas XR. Complexity and stigma of pediatric obesity. Child Obes. 2021;17(4):229\u201340.","journal-title":"Child Obes"},{"issue":"11","key":"2723_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/dom.14133","volume":"22","author":"R Haws","year":"2020","unstructured":"Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet\u2013Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"2723_CR29","unstructured":"Rhythm Pharmaceuticals: Rhythm pharmaceuticals announces IMCIVREE\u00ae (setmelanotide) granted marketing authorization by European Commission for Treatment of obesity and control of hunger in Bardet\u2013Biedl Syndrome. https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-imcivreer-setmelanotide-granted#:~:text=The%20European%20Commission%20(EC)%20has%20authorized%20setmelanotide%20for%20the%20treatment,years%20of%20age%20and%20above (2022). Accessed on 12 Sept 2022."},{"key":"2723_CR30","unstructured":"FDA: Setmelanotide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213793s000lbl.pdf (2020). Accessed 22 Aug 2022."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02723-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T23:03:40Z","timestamp":1688684620000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02723-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2723"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02723-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was provided by the US Pearl Independent Review Board (IRB) under the Exempt category.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EF has received consulting fees from Rhythm Pharmaceuticals, Inc.; participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc.; and is a clinical investigator for clinical trials of setmelanotide in Bardet\u2013Biedl syndrome for Rhythm Pharmaceuticals, Inc. UGM and CH are employees of Rhythm Pharmaceuticals, Inc. and receive stock or stock options with Rhythm Pharmaceuticals, Inc. MY, AG, and EH are employees of Analysis Group, Inc., which received funding to conduct this study. MLC is a former employee of Analysis Group, Inc., but was an employee during the conduct of this study. JP receives research support from Rhythm Pharmaceuticals, Inc. as a co-investigator for the Setmelanotide Phase 2 Treatment of Obesity in Rare Genetic Disorders (ClinicalTrials.gov Identifier NCT03013543) and as a co-investigator of a study examining unmet medical needs related to obesity in people with Bardet\u2013Biedl syndrome. AMH receives grant funding from the Weston Family Microbiome Initiative and Canadian Institutes of Health Research, is a member of the BBS advisory board for Rhythm Pharmaceuticals, Inc., is a member of the 2023 Novo Nordisk Canada Pediatric Expert Obesity National Advisory Board, 2021\u20132022 Somatrogon advisory board for Pfizer, Inc., and is a clinical investigator for trials with Rhythm Pharmaceuticals, Inc. and Levo Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}